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QDoes cardiac resynchronization therapy (CRT) ex-
ert some of its benefits on mortality through a
reduction in ventricular tachycardia (VT) or ven-
tricular fibrillation (VF), and if so, is this linked to
its effects on dyssynchrony? In this issue of the
Journal, Kutyifa et al. (1) investigate the interplay
between CRT, dyssynchrony, and the composite
outcome of VT, VF, or death in the MADIT-CRT
(Multicenter Automatic Defibrillator Implantation
Trial-Cardiac Resynchronization Therapy) trial.
See page 432
Patients with left ventricular systolic dysfunction
(LVSD) who do not have severe symptoms of heart
failure are more likely to die suddenly than of severe
heart failure. Implanted cardioverter-defibrillators
(ICDs) exert a moderate reduction in all-cause
mortality in this population, solely by reducing
sudden death, thereby establishing an electrical
origin for a large proportion of sudden deaths in
this setting. However, patients still have to die of
something. Reducing the rate of sudden death
increases the time at risk of other modes of death,
which will increase the proportion of, but not the
rate of deaths from, worsening heart failure after
ICD implantation. ICDs might also exacerbate
cardiac dysfunction and heart failure due to pacing-
induced dyssynchrony, right ventricular damage
from electrical shocks, and other effects (2). CRT
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contents of this paper to disclose.ould prevent or help manage worsening heart
ailure by reducing dyssynchrony, thus acting syn-
rgistically with an ICD to reduce all-cause mor-
ality. There are some concerns that biventricular
acing might provoke ventricular arrhythmias in
ome patients (3), but improved cardiac function
ight also be expected to reduce them. The
ARE-HF (Cardiac Resynchronization-Heart
ailure) study suggested that CRT pacing, without
n ICD function, could reduce the rate of sudden
eath substantially (4). Reducing the rate of ven-
ricular arrhythmias may reduce the rate of ICD
hocks (5), and because ICDs are not always effec-
ive, mortality.
To address these issues, the MADIT-CRT trial
nvestigated the outcome of patients with few or no
ymptoms of heart failure (25% did not even require
diuretic) but who had a left ventricular ejection
raction of 30% or less and a QRS duration of 130
s or more who were about to receive an ICD (6).
atients were randomly assigned to receive cardiac
esynchronization therapy with a defibrillator
CRT-D) or an ICD. During a median follow-up
f 2.4 years, patients assigned to CRT-D had a
ower rate of hospitalizations for heart failure com-
ared to patients assigned to an ICD, but mortality
ates were similar. Benefits were greater in patients
ith QRS durations 150 ms. Subsequent reports
uggested that benefit was confined to patients with
eft bundle branch block (LBBB), but these patients
lso had a substantially longer QRS duration (6).
his has led to confusion over whether QRS
orphology or duration is the better method of
electing patients for CRT.
Kutyifa et al. (1) now show that measurements of
yssynchrony at baseline do not predict the risk of
erious arrhythmias overall or when subgrouped by
RS morphology. Importantly, patients with more
evere dyssynchrony did not have a worse outcome,
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446even if they only received an ICD. This finding
contrasts with several observational studies, but
large randomized trials suggest that, after correcting
for left ventricular ejection fraction, interventricular
dyssynchrony is actually associated with a favorable
outcome whether or not the patient receives CRT
(7,8). That may be because the dyssynchronous
ventricle looks worse than it actually is (7,8).
The MADIT-CRT investigators have already
reported that favorable left ventricular remodeling
was associated with a reduction in arrhythmias (9).
Kutyifa et al. (1) now extend that to the investiga-
tion of the relationship between changes in dyssyn-
chrony and arrhythmias. They found that the sub-
group of patients with LBBB was more likely to
have an improvement in dyssynchrony and that this
improvement is associated with a subsequent reduc-
tion in the risk of arrhythmias and death. Post-hoc
analysis may be valuable, but it is often difficult to
interpret.
The first major limitation of this analysis is that
only 1,077 (59%) of 1,820 patients included in the
main study had baseline images of adequate quality
for evaluation in this analysis, and only 809 (44%)
had paired images. The investigators used a 12-
segment model to assess dyssynchrony using
speckle-tracking and the standard deviation of time
to peak strain. This is only one of many methods of
assessing dyssynchrony that have proved notori-
ously unreliable in predicting the outcome after
CRT (10). The investigators used an arbitrary 15%
cutoff as evidence of an improvement in dyssynchrony
and did not explore other thresholds. There were few
events in patients assigned to ICD who did not have
LBBB, casting doubt on the apparent the interaction
between CRT and QRS morphology.
However, the major confounder in this analysis is
that patients with LBBB differed from other pa-
tients in many ways. Patients with LBBB in the
MADIT-CRT trial had a QRS duration of 163 ms
and 44% had ischemic heart disease, compared to
146 ms and 80%, respectively, for patients who did
not have LBBB (6). Patients with LVSD due to
ischemic heart disease are likely to have more
myocardial scar than patients with dilated cardio-
myopathy. Full-thickness scar cannot contract, and
partial thickness scar is likely to have both delayed
and reduced contraction. Scarred myocardium will
contribute to dyssynchrony but cannot improve
with CRT.
One interpretation of these data is that LBBB is
a marker for dilated cardiomyopathy and that such
patients have a greater chance of their left ventric-ular function improving with CRT, or indeed other
interventions (11), and a lower risk of ventricular
arrhythmias, whether or not ventricular function
improves. In contrast, patients with myocardial scar
are less likely to have LBBB, are more prone to
arrhythmias, are less likely to have reductions in
dyssynchrony or improvements in left ventricular
remodeling, and have an intrinsically worse prog-
nosis with or without CRT. Thus, the link between
changes in dyssynchrony and arrhythmias may be
circumstantial rather than cause and effect. Al-
though Kutyifa et al. (1) found that the association
between change in dyssynchrony and arrhythmias
was independent of the effect of CRT ventricular
remodeling in their multivariable statistical model,
it is not clear, in such a complex model with
complex measures and relatively few events, that
this finding is reliable. Why should change in
dyssynchrony be associated with a reduction in
arrhythmias when there was no relationship be-
tween arrhythmias and baseline measurements of
dyssynchrony? Randomized trials consistently show
that left ventricular function is less likely to improve
with CRT in patients with ischemic heart disease
and yet these patients get the same relative mortal-
ity benefit (12,13). Because patients with ischemic
heart disease are at greater absolute risk of events,
their absolute benefits from CRT may also be
greater.
There are several mechanisms by which CRT
might reduce the rate of VT/VF. It is possible that
reduced electrical or mechanical dyssynchrony di-
rectly reduces the risk of such events. Alternatively,
improved cardiac function could reduce the overall
risk of arrhythmias as observed with other therapies.
However, it is also possible that CRT reduces the
risk of VT/VF triggered by pauses. Many have
jumped to the conclusion that because ICDs are
designed to shock VT/VF, that must be their
mechanism of action. It is not clear that the heart
has “read the script.” Could the predominant ben-
efit of an ICD be prevention of pause-dependent
VT or even bradyarrhythmic sudden death (7,8)?
This hypothesis has not been tested. If true, then
CRT could be as, or more, effective than CRT-D in
reducing mortality. CRT might simply be a way of
preventing bradycardia without exacerbating dys-
synchrony. Interestingly, when ICDs are pro-
grammed to hesitate for a few more seconds before
delivering a shock, the rate of shocks drops by more
than two-thirds without loss of benefit, demon-
strating that most VT is self-limiting (2).
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447In conclusion, CRT has a broad range of direct
effects on cardiac function, including reductions in
atrioventricular and ventricular dyssynchrony, mi-
tral regurgitation, and bradyarrhythmias with sec-
ondary consequences, such as improvement in ven-
tricular structure and function. The main mechanism of
benefit is likely to vary from one patient to the nextet al. Effectiveness of cardiac resyn-
1
Circulation 2010;12patients for CRT or to explain its benefits is likely
to be misleading.
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